Anuh Pharma Ltd: Key Updates Ahead of Annual General Meeting

In the bustling world of pharmaceuticals, Anuh Pharma Ltd, a prominent player in the health care sector, is making headlines with several important announcements as it gears up for its 65th Annual General Meeting (AGM). The company, known for its extensive portfolio of bulk drugs and chemicals, including active pharmaceutical ingredients and corticosteroids, is set to address its shareholders on August 22, 2025.

Dividend and Voting Details

A significant update for shareholders is the revised record date for the final dividend of the fiscal year 2024-2025. Initially set for an earlier date, the record date has now been moved to Friday, August 15, 2025. This adjustment is crucial for shareholders aiming to receive the final dividend, should it be declared and approved at the AGM. Additionally, this date will determine eligibility for voting through the remote e-voting facility, ensuring shareholders can participate in key decisions from afar.

Communication Efforts

In a move to ensure all shareholders are well-informed, Anuh Pharma Ltd has dispatched physical communications to those who have not registered their email addresses. This initiative aligns with the requirements of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided a weblink for accessing the Annual Report on its website, ensuring transparency and accessibility of information.

AGM and E-voting Information

The upcoming AGM, scheduled for August 22, 2025, at the Hall of Harmony, Nehru Centre in Mumbai, will be a pivotal event for the company. In compliance with Regulation 47 of the SEBI regulations, the meeting details have been widely publicized, including newspaper advertisements in both English and Marathi editions. This ensures that all stakeholders are aware of the proceedings and can participate effectively.

Market Performance and Outlook

As of July 27, 2025, Anuh Pharma Ltd’s stock closed at INR 97.69, reflecting a recovery from its 52-week low of INR 74.25 in March 2025. The company’s market capitalization stands at INR 10.04 billion, with a price-to-earnings ratio of 21.19. These figures indicate a stable financial position, with potential growth opportunities as the company continues to innovate in its product offerings, including macrolides, anti-malarial, and anti-hypertension products.

As Anuh Pharma Ltd prepares for its AGM, stakeholders are keenly watching for updates on dividend declarations and strategic directions. The company’s commitment to transparency and shareholder engagement is evident in its proactive communication efforts, setting the stage for a productive meeting.